Old Web
English
Sign In
Acemap
>
Paper
>
Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs)
Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs)
2015
J. von Pawel
Jennifer F. Tseng
Mircea Dediu
Christian Schumann
Berta Moritz
Jeanne Mendell
Xiaoping Jin
Wenqin Feng
Catherine Copigneaux
Robert A. Beckman
Keywords:
Erlotinib
Patritumab
Cancer research
Immunology
Medicine
Internal medicine
Oncology
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]